## BREAKING ADVANCES

3707  Highlights from Recent Cancer Literature

## REVIEWS

3709  ATP-Citrate Lyase: A Key Player in Cancer Metabolism

Nouheen Zaidi, Johannes V. Swinnen, and Karine Smans

3715  Awaiting a New Era of Cancer Immunotherapy

Cheng William Hong and Qi Zeng

## MEETING REPORT

3720  The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer Medicine

The Global Cancer Genomics Consortium

## CLINICAL STUDIES

3725  Prognostic PET 18F-FDG Uptake Imaging Features Are Associated with Major Oncogenic Alterations in Patients with Resected Non–Small Cell Lung Cancer

Viswam S. Nair, Olivier Gevaert, Guido Davidzon, Sandy Napel, Edward E. Graves, Chuong D. Hoang, Joseph B. Shrager, Andrew Quon, Daniel L. Rubin, and Sylvia K. Plevritis

Précis: The molecular association of 18F-FDG uptake and positron emission tomography image features with gene expression can enhance our understanding of lung cancer progression and may facilitate new management strategies for patients.

## MICROENVIRONMENT AND IMMUNOLOGY

3735  NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells


Précis: Using a whole-colon tissue culture system, this study defines an immediately translatable combination of pharmacologic and biologic factors to promote the infiltration of colon tumors with cytolytic T-effector cells, a feature tightly correlated with improved survival outcomes regardless of tumor staging.

3744  Molecular Identification of GD3 as a Suppressor of the Innate Immune Response in Ovarian Cancer

Tonya J. Webb, Xiangming Li, Robert L. Giuntoli II, Pablo H.J. Lopez, Christoph Heuser, Ronald L. Schnaar, Moriya Tsuji, Christian Kurts, Mathias Oelke, and Jonathan P. Schneck

Précis: Findings identify an endogenous cell surface glycolipid as an immune inhibitory molecule, which, when secreted by ovarian cancers, can block natural killer T-cell activation, offering a novel immunomodulatory target in this setting.

## MOLECULAR AND CELLULAR PATHOBIOLOGY

3753  Molecular Signature of Smoking in Human Lung Tissues

Yohan Bossé, Dirkje S. Postma, Don D. Sin, Maxime Lamontagne, Christian Couture, Nathalie Gaudreault, Philippe Joubert, Vivien Wong, Mark Elliott, Maarten van den Berge, Corry A. Brandsma, Catherine Tribouley, Vladislav Malkov, Jeffrey A. Tsou, Gregory J. Opiteck, James C. Hogg, Andrew J. Sandford, Wim Timens, Peter D. Paré, and Michel Laviolette

Précis: This study used whole-genome gene expression to show the long-term impact of smoking on gene expression in nontumor lung tissues from patients with lung cancer.
The Oncogenic Lung Cancer Fusion Kinase CD74-ROS Activates a Novel Invasiveness Pathway through E-Syt1 Phosphorylation

Hyun Jung Jun, Hannah Johnson, Roderick T. Bronson, Sebastien de Feraudy, Forest White, and Alain Charest

Précis: Findings establish the oncogenicity of a recently discovered ROS fusion kinase in lung adenocarcinoma and show its utility as a therapeutic target in this setting.

Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia

Constance Baer, Rainer Claus, Lukas P. Frenzel, Manuela Zucknick, Yoon Jung Park, Lei Gu, Dieter Weichenhan, Martina Fischer, Christian Philipp Pallasch, Esther Herpel, Michael Rehli, John C. Byrd, Clemens-Martin Wendtner, and Christoph Plass

Précis: Findings extend the concept that epigenetic mechanisms are involved in cancer, influencing not only transcriptional control of protein coding genes but also microRNAs in chronic lymphocytic leukemia.

Autoregulatory Mechanisms of Phosphorylation of Checkpoint Kinase 1

Jingna Wang, Xiangzi Han, and Youwei Zhang

Précis: This study reveals a novel mechanism underlying cell-cycle checkpoint activation with implications for a novel approach to cancer therapy that involves artificially activating checkpoints under normal growth conditions.

Identification of a Molecular Signature Underlying Inhibition of Mammary Carcinoma Growth by Dietary N-3 Fatty Acids

Weiqin Jiang, Zongjian Zhu, John N. McGinley, Karam El Bayoumy, Andrea Manni, and Henry J. Thompson

Précis: This study identifies the pathways modulated by dietary fatty acid ratios in a rat model of breast cancer, with implications for cancer prevention.

Manganese Superoxide Dismutase Regulates a Metabolic Switch during the Mammalian Cell Cycle

Ehab H. Sarsour, Amanda L. Kalen, Zhen Xiao, Timothy D. Veenstra, Leena Chaudhuri, Sujatha Venkataraman, Philip Reigan, Garry R. Buettnner, and Prabhat C. Goswami

Précis: Studies of cells deficient in MnSOD, a mitochondrial enzyme that controls cellular redox flux, show that MnSOD regulates glucose consumption during transit through the cell cycle, implying a role in the Warburg Effect.

Loss of Rassfla Synergizes with Deregulated Runx2 Signaling in Tumorigenesis

Louise van der Weyden, Angelos Papaspyropoulos, George Poulougiannis, Alistair G. Rust, Mamunur Rashid, David J. Adams, Mark J. Aron, and Eric O’Neill

Précis: Findings reveal a new intersection between Ras signaling and the HIPPO signaling pathway for cell-cycle and survival control that is critical in leukemia development.

MET Signaling Regulates Glioblastoma Stem Cells

Kyeung Min Joo, Juyoun Jin, Eunhee Kim, Kang Ho Kim, Yonghyun Kim, Bong Gu Kang, Yoon-Jung Kang, Justin D. Lathia, Kwang Ho Cheong, Paul H. Song, Hyunggee Kim, Ho Jun Seol, Doo-Sik Kong, Jung Il Lee, Jeremy N. Rich, Jeonggou Lee, and Do-Hyun Nam

Précis: The results of this study suggest that MET kinase may represent a promising therapeutic target in these aggressive brain tumors, a timely issue given the late-stage clinical development of MET kinase inhibitors.

CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells

Marco Velasco-Velázquez, Xuanmao Jiao, Marisol De La Fuente, Timothy G. Pestell, Adam Ertel, Michael P. Lisanti, and Richard G. Pestell

Précis: CCR5 antagonists, originally developed as HIV-entry inhibitors, reduce invasiveness and metastatic capability of breast cancer cells with basal phenotype and therefore may be used to prevent metastasis in patients with this currently nontargetable subtype of breast cancer.
Embryonic Protein Nodal Promotes Breast Cancer Vascularization
Daniela F. Quail, Logan A. Walsh, Guihua Zhang, Scott D. Findlay, Juan Moreno, Laura Fung, Amber Ablack, John D. Lewis, Susan J. Done, David A. Hess, and Lynne-Marie Postovit

**Précis:** Findings suggest that inhibitors of the developmental regulator Nodal may be useful as targeted therapies to block vascularization of breast cancers.

Numb Regulates Stability and Localization of the Mitotic Kinase PLK1 and Is Required for Transit through Mitosis
Travis L. Schmit, Minakshi Nihal, Mary Ndiaye, Vijayasaradhi Setaluri, Vladimir S. Spiegelman, and Nihal Ahmad

**Précis:** A developmental protein, Numb, which functions in cell fate determination, is found to exert a tumor-suppressive function during symmetric cell division.

Fibulin-3 Promotes Glioma Growth and Resistance through a Novel Paracrine Regulation of Notch Signaling

**Précis:** This seminal work highlights the major regulatory role of the tumor extracellular matrix on Notch signaling to promote glioma invasion and survival, with immediate clinical implications for improvement of adjuvant treatment strategies in malignant brain tumors.

### CORRECTIONS

**Correction:** YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts

**Correction:** Identification and Characterization of Nuclease-Stabilized RNA Molecules That Bind Human Prostate Cancer Cells via the Prostate-Specific Membrane Antigen

### ABOUT THE COVER

Activation of chemokine receptors on breast cancer cells can control their invasiveness. Analyzing microarray data from human breast cancer samples, increased expression of CCR5 in the basal subtype was found. Using in vivo and ex vivo bioluminescence in xenograft models, it was found that the CCR5 antagonist Maraviroc reduced lung colonization and metastasis in basal breast cancer cells. These results may lead to a new use of CCR5 antagonists as antimetastatic drugs. For details, see article by Velasco-Velázquez and colleagues on page 3839 of this issue.
Cancer Research
72 (15)

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/72/15

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/72/15.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.